<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153474</url>
  </required_header>
  <id_info>
    <org_study_id>SP-LP PCNL</org_study_id>
    <nct_id>NCT04153474</nct_id>
  </id_info>
  <brief_title>Exit Strategy After Percutaneous Nephrolithotomy: Large or Small Bore Tube?</brief_title>
  <official_title>Exit Strategy After Percutaneous Nephrolithotomy: Large or Small Bore Tube? Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regarding to the distribution of nephrostomy tube (NT) size usage by country. There was a
      clear distinction between countries that used solely the small bore (SB) NT (Chile and
      Australia) and those that used solely the large bore (LB) NT (Czech Republic and Japan).
      There is also a trend toward SB NT in North America (~75% in USA and Canada) and toward LB NT
      in South America (~80% in Argentina and Mexico). In Europe the trend is equal (~50% in
      Germany, France, Greece and UK). Based on previous data and in view of conflicting data about
      postoperative complication including extravasation, bleeding and hemoglobin change and pain
      between previous studies, we will conduct this randomised trial comparing SB and LB NT
      following PNL.

      Our aim to evaluate the safety of small versus large bore NT reporting complications using
      the Clavien-Dindo system with categorisation of PNL-specific complications
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hemoglobin reduction difference between groups</measure>
    <time_frame>8 months</time_frame>
    <description>measured in gram/liter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain score</measure>
    <time_frame>8 months</time_frame>
    <description>Assessed by Visual Analogue Scale (VAS) points from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative patient satisfaction</measure>
    <time_frame>8 months</time_frame>
    <description>measured by The Freiburg Index of Patient Satisfaction (FIPS score) from 1 to 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall postoperative complication</measure>
    <time_frame>8 months</time_frame>
    <description>assesed by Clavien-Dindo system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Urolithiasis</condition>
  <condition>Nephrolithotomy</condition>
  <condition>Percutaneous Nephrolithotomy (PNL)</condition>
  <condition>Nephrostomy Tube (NT)</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>large-bore nephrostomy tube (LBNT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>large-bore 22 french nephrostomy tube (LBNT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>small-bore nephrostomy tube (SBNT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>small-bore 14 french nephrostomy tube (SBNT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>large-bore nephrostomy tube (LBNT)</intervention_name>
    <description>large-bore 22 french nephrostomy tube (LBNT)</description>
    <arm_group_label>large-bore nephrostomy tube (LBNT)</arm_group_label>
    <other_name>LBNT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>small-bore nephrostomy tube (SBNT)</intervention_name>
    <description>small-bore 14 french nephrostomy tube (SBNT)</description>
    <arm_group_label>small-bore nephrostomy tube (SBNT)</arm_group_label>
    <other_name>SBNT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Staghorn calculi

          2. Renal pelvis stones =&gt;2 cm

          3. Lower pole stones= &gt;1.5 cm

          4. upper ureteral calculi =&gt;1.5 cm

          5. SWL-resistant stones

        Exclusion Criteria:

          1. Age &lt;18 years or Pregnancy

          2. Tubeless PNL

          3. Need for 3 percutaneous tracts intraoperative

          4. Morbid obesity (BMI &gt;40)

          5. Refuse to complete study requirements

          6. Tumour in the presumptive access tract area or Potential malignant kidney tumour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed Shoma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Percutaneous nephrolithotomy (PNL)</keyword>
  <keyword>Nephrostomy tube (NT)</keyword>
  <keyword>Pain</keyword>
  <keyword>Patient satisfaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

